Acute lymphoblastic leukemia infant · 2 regimens
Cost vs Efficacy
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Blinatumomab monotherapy Variant #05 | KMT2A | R 728 965 | 56d | — | ~7.7 mo | ~1 | ~R 728 965 PFS proxy · indirect | 2 |
Cyclophosphamide, Etoposide, Methotrexate Variant #01 | KMT2A | R 3 036 | 42d | — | — | ~1 | ~R 3 036 indirect | — |
2 of 2 regimens shown